Statistics and Infographics

Singapore is a thriving hub for clinical trials in the Asia-Pacific region, renowned for its strategic location, advanced medical infrastructure, and rigorous regulatory standards. Between 2016 to 2022, an average of 225 trials were initiated in Singapore each year. Out of these numbers, an average of 95 were drug trials.

Clinical trials in Singapore encompass various phases, from safety testing (Phase I) to evaluation of treatment efficacy and monitoring of side effects (Phase II), and post-approval monitoring (Phase IV). Specifically, about 41% of the drug trials conducted in Singapore between 2016 to 2022 are large-scale efficacy trials (Phase III).

*Data accurate as of July 2024

The nation's strengths lie in diverse therapeutic areas, including oncology, infectious diseases, cardiovascular, gastrointestinal and metabolic disorders. Singapore is actively expanding into emerging fields of research, such as personalized medicine and digital health, providing opportunities for cutting-edge studies.

Top 5 Therapeutic Areas

*Data accurate as of July 2024

It hosts prominent clinical research centres like National University Hospital (NUH), Singapore General Hospital (SGH), National Cancer Centre Singapore, KK Women’s and Children’s hospital, which provide state-of-the-art facilities and experienced teams for conducting clinical trials. Singapore actively collaborates with global pharmaceutical companies (including Novatis AG, Pfizer, F. Hoffmann-La Roche AG, Eli Lily and Company, Bistol-Myers Squibb, Bayer AG and Merck & Co., GlaxoSmithKline), academic institutions such as National University of Singapore (NUS) and Duke-NUS Medical School, and international organizations, fostering partnerships that enhance the quality and reach of clinical trials.

Top 20 Trial Sponsors

*Data accurate as of July 2024